<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01807923</url>
  </required_header>
  <id_info>
    <org_study_id>VX12-809-103</org_study_id>
    <nct_id>NCT01807923</nct_id>
  </id_info>
  <brief_title>A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation</brief_title>
  <acronym>TRAFFIC</acronym>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to evaluate the efficacy of lumacaftor in combination
      with ivacaftor at Week 24 in participants aged 12 years and older with cystic fibrosis (CF)
      who are homozygous for the F508del mutation on the CF transmembrane conductance regulator
      (CFTR) gene.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 3, randomized, double-blind, placebo-controlled, parallel-group multicenter
      study of orally administered lumacaftor in combination with ivacaftor in participants aged 12
      years and older with CF who are homozygous for the F508del-CFTR mutation.

      The study included a Screening Period (Day -28 through Day -1), a Treatment Period (Day 1
      [first dose of study drug] to Week 24 ± 5 days), and a Safety Follow-up Visit (4 weeks ± 7
      days after the Week 24 Visit).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24</measure>
    <time_frame>Baseline, Week 16 and 24</time_frame>
    <description>Absolute change from baseline at Week 24 was assessed as the average treatment effect at Week 16 and at Week 24. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline in Percent Predicted FEV1 at Week 24</measure>
    <time_frame>Baseline, Week 16 and 24</time_frame>
    <description>Assessed as the average treatment effect at Week 16 and at Week 24. FEV1 and percent predicted FEV1 are defined in Outcome Measure (OM) 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Body Mass Index (BMI) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Response Based on Percent Predicted FEV1</measure>
    <time_frame>Week 16 and 24</time_frame>
    <description>A participant was considered as a responder if the participant had &gt;=5% increase from baseline in average percent predicted FEV1 at Week 16 and at Week 24 (relative change). FEV1 and percent predicted FEV1 are defined in OM 1. A participant with a missing average relative change from baseline in percent predicted FEV1 at Week 16 and at Week 24 was considered as a non-responder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Pulmonary Exacerbation Events</measure>
    <time_frame>through Week 24</time_frame>
    <description>The total number of days on study is equal to the Week 24 date or the last dose date (whichever occurred last) minus the first dose date plus 1. The total number of years (48 weeks) on study is equal to the number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Weight at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in BMI-for-age Z-score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Z-Score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from -infinity to + infinity; 0: same mean, &gt;0: a greater mean, and &lt;0: a lesser mean than the standard. BMI-for-age z-score was calculated by using Centers for Disease Control and Prevention (CDC) growth charts for the pediatric population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-First Pulmonary Exacerbation</measure>
    <time_frame>through Week 24</time_frame>
    <description>Time to first pulmonary exacerbation was assessed using Cox Regression. For participants who completed 24 weeks of treatment, participants without a pulmonary exacerbation before treatment completion were considered censored at the time of treatment completion or at the Week 24 Visit (whichever occurred last). For participants who prematurely discontinued study treatment, participants without a pulmonary exacerbation through the Week 24 Visit were considered censored at the time of the Week 24 Visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least 1 Pulmonary Exacerbation Event</measure>
    <time_frame>through Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>EQ-5D-3L: participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The 5 dimensional 3-level systems are converted into a single index utility score. Values for theoretically possible health states are calculated using a regression model and weighted according to the social preferences of the Unites States (US) general population. For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The EQ-5D-3L VAS records the participant's self-rated health on a vertical, visual analogue scale where the best state a participant can imagine is marked 100 and the worst state a participant can imagine is marked 0, higher scores indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The TSQM is a 14-item self-administered questionnaire which measures participants' experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)</measure>
    <time_frame>up to Week 28</time_frame>
    <description>AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Nonserious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or that was newly developed at or after the initial dosing of study drug to 28 days after the last dose of study drug is considered treatment-emergent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)</measure>
    <time_frame>For C3-6h: 3 to 6 hours after morning dose on Day 1 and 15, Week 4 and 8; For C3-6h,avg 3 to 6 hours after morning dose on Day 15, Week 4 and 8; For Ctrough and Ctrough,avg: before morning dose on Week 4, 8, and 16</time_frame>
    <description>Ctrough, Ctrough, avg, C3-6h, and C3-6h, avg for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 15, and Weeks 4 and 8 and Ctrough, ave is average of individual pre-dose observed concentrations across Weeks 4, 8, and 16. This outcome was not planned to be assessed in Placebo arm.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">559</enrollment>
  <condition>Cystic Fibrosis, Homozygous for the F508del CFTR Mutation</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUM 600 mg qd/IVA 250 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LUM 400 mg q12h/ IVA 250 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumacaftor Plus Ivacaftor Combination</intervention_name>
    <description>Fixed dose combination tablet</description>
    <arm_group_label>LUM 600 mg qd/IVA 250 mg q12h</arm_group_label>
    <arm_group_label>LUM 400 mg q12h/ IVA 250 mg q12h</arm_group_label>
    <other_name>VX-809+VX-770, LUM+IVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <description>Film-coated tablet</description>
    <arm_group_label>LUM 600 mg qd/IVA 250 mg q12h</arm_group_label>
    <other_name>VX-770, IVA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of CF

          -  Homozygous for the F508del CFTR mutation

          -  Forced expiratory volume in 1 second (FEV1) greater than or equal to (&gt;=) 40 percent
             (%) and less than or equal to (=&lt;) 90% of predicted normal for age, sex, and height

          -  Willing to remain on a stable CF medication regimen through Week 24 or, if applicable,
             the Safety Follow up Visit

        Exclusion Criteria:

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before first dose
             of study drug

          -  History of solid organ or hematological transplantation

          -  History of alcohol or drug abuse in the past year

          -  Ongoing or prior participation in an investigational drug study (including studies
             investigating lumacaftor and/or ivacaftor) within 30 days of screening

          -  Use of strong inhibitors, moderate inducers or strong inducers of Cytochrome P450 3A
             (CYP3A) within 14 days before Day 1 of dosing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madera</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gainsville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Park Ridge</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broadmeadow</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brno</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plzen-Bory</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 5</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Strasbourg Cedex 2</city>
        <state>Bas Rhin</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roscoff</city>
        <state>Finistere</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 14</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paris Cedex 15</city>
        <state>Paris</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bron Cedex</city>
        <state>Rhone</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pierre Benite</city>
        <state>Rhone</state>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuebingen</city>
        <state>Baden Wuerttemberg</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koeln</city>
        <state>Nordrhein Westfalen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tallaght</city>
        <state>Dublin</state>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Uppsala</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southhampton</city>
        <state>Hampshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 4, 2013</study_first_submitted>
  <study_first_submitted_qc>March 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2013</study_first_posted>
  <results_first_submitted>August 1, 2015</results_first_submitted>
  <results_first_submitted_qc>August 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 31, 2015</results_first_posted>
  <disposition_first_submitted>May 8, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>May 8, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">June 2, 2015</disposition_first_posted>
  <last_update_submitted>August 1, 2015</last_update_submitted>
  <last_update_submitted_qc>August 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo matched to lumacaftor (LUM, VX-809) and ivacaftor (IVA, VX-770) tablet every 12 hours (q12h), up to Week 24.</description>
        </group>
        <group group_id="P2">
          <title>LUM 600 mg qd/IVA 250 mg q12h</title>
          <description>LUM 600 milligram (mg) plus IVA 250 mg fixed-dose combination (FDC) tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
        </group>
        <group group_id="P3">
          <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
          <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="187"/>
                <participants group_id="P2" count="185"/>
                <participants group_id="P3" count="187"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="182"/>
                <participants group_id="P2" count="179"/>
                <participants group_id="P3" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal of Consent (not due to AE)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Eligible (Genotype)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized But Not Treated</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) included all randomized participants who received any amount of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
        </group>
        <group group_id="B2">
          <title>LUM 600 mg qd/IVA 250 mg q12h</title>
          <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
        </group>
        <group group_id="B3">
          <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
          <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="184"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="182"/>
            <count group_id="B4" value="549"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.0" spread="10.80"/>
                    <measurement group_id="B2" value="24.7" spread="9.71"/>
                    <measurement group_id="B3" value="25.5" spread="10.09"/>
                    <measurement group_id="B4" value="25.1" spread="10.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="86"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="97"/>
                    <measurement group_id="B3" value="98"/>
                    <measurement group_id="B4" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24</title>
        <description>Absolute change from baseline at Week 24 was assessed as the average treatment effect at Week 16 and at Week 24. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.</description>
        <time_frame>Baseline, Week 16 and 24</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received any amount of study drug. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) at Week 24</title>
          <description>Absolute change from baseline at Week 24 was assessed as the average treatment effect at Week 16 and at Week 24. FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Hankinson and Wang standards were used to calculate percent predicted FEV1 (for age, gender, race, and height). The Hankinson standard was used for male participants 18 years and older and female participants 16 years and older. The Wang standard was used for male participants aged 12 to 17 years and for female participants aged 12 to 15 years.</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received any amount of study drug. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.44" spread="0.524"/>
                    <measurement group_id="O2" value="3.59" spread="0.525"/>
                    <measurement group_id="O3" value="2.16" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using mixed-effects model for repeated measures (MMRM) model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (less than (&lt;)18 versus greater than equal to (&gt;=18) years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM</method>
            <param_type>Least Squares (LS) Mean Difference</param_type>
            <param_value>4.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.62</ci_lower_limit>
            <ci_upper_limit>5.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model, as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.18</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline in Percent Predicted FEV1 at Week 24</title>
        <description>Assessed as the average treatment effect at Week 16 and at Week 24. FEV1 and percent predicted FEV1 are defined in Outcome Measure (OM) 1.</description>
        <time_frame>Baseline, Week 16 and 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline in Percent Predicted FEV1 at Week 24</title>
          <description>Assessed as the average treatment effect at Week 16 and at Week 24. FEV1 and percent predicted FEV1 are defined in Outcome Measure (OM) 1.</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.913"/>
                    <measurement group_id="O2" value="6.39" spread="0.914"/>
                    <measurement group_id="O3" value="3.99" spread="0.923"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.27</ci_lower_limit>
            <ci_upper_limit>9.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model, as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>4.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.86</ci_lower_limit>
            <ci_upper_limit>6.80</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Body Mass Index (BMI) at Week 24</title>
        <description>BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Body Mass Index (BMI) at Week 24</title>
          <description>BMI was defined as weight in kilogram (kg) divided by height*height in square meter (m^2).</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>kilogram per square meter (kg/m^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.19" spread="0.070"/>
                    <measurement group_id="O2" value="0.35" spread="0.070"/>
                    <measurement group_id="O3" value="0.32" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline BMI.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1122</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.04</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model, as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1938</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score at Week 24</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), the scaled score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life.</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="176"/>
                <count group_id="O3" value="172"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="1.161"/>
                    <measurement group_id="O2" value="4.98" spread="1.178"/>
                    <measurement group_id="O3" value="2.60" spread="1.192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline CFQ-R respiratory domain score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0168</p_value>
            <p_value_desc>This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.</p_value_desc>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.70</ci_lower_limit>
            <ci_upper_limit>7.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model, as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3569</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.69</ci_lower_limit>
            <ci_upper_limit>4.69</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Response Based on Percent Predicted FEV1</title>
        <description>A participant was considered as a responder if the participant had &gt;=5% increase from baseline in average percent predicted FEV1 at Week 16 and at Week 24 (relative change). FEV1 and percent predicted FEV1 are defined in OM 1. A participant with a missing average relative change from baseline in percent predicted FEV1 at Week 16 and at Week 24 was considered as a non-responder.</description>
        <time_frame>Week 16 and 24</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Response Based on Percent Predicted FEV1</title>
          <description>A participant was considered as a responder if the participant had &gt;=5% increase from baseline in average percent predicted FEV1 at Week 16 and at Week 24 (relative change). FEV1 and percent predicted FEV1 are defined in OM 1. A participant with a missing average relative change from baseline in percent predicted FEV1 at Week 16 and at Week 24 was considered as a non-responder.</description>
          <population>FAS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3"/>
                    <measurement group_id="O2" value="46.4"/>
                    <measurement group_id="O3" value="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Odds Ratio (OR) and 95% confidence intervals (Cis) are Mantel-Haenszel estimates. P values are from a Cochran-Mantel-Haenszel test stratified by sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.9378</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8786</ci_lower_limit>
            <ci_upper_limit>4.5941</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0023</p_value>
            <p_value_desc>This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.0592</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2920</ci_lower_limit>
            <ci_upper_limit>3.2819</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Pulmonary Exacerbation Events</title>
        <description>The total number of days on study is equal to the Week 24 date or the last dose date (whichever occurred last) minus the first dose date plus 1. The total number of years (48 weeks) on study is equal to the number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.</description>
        <time_frame>through Week 24</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Pulmonary Exacerbation Events</title>
          <description>The total number of days on study is equal to the Week 24 date or the last dose date (whichever occurred last) minus the first dose date plus 1. The total number of years (48 weeks) on study is equal to the number of days on study divided by 336. Pulmonary exacerbation events per year (48 weeks) are reported.</description>
          <population>FAS.</population>
          <units>pulmonary exacerbation events per year</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.07"/>
                    <measurement group_id="O2" value="0.77"/>
                    <measurement group_id="O3" value="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using regression analysis for a negative binomial distribution with sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70) as covariates with the logarithm of time on study as the offset.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0491</p_value>
            <method>Negative Binomial Regression</method>
            <param_type>Event Rate Ratio</param_type>
            <param_value>0.7186</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5170</ci_lower_limit>
            <ci_upper_limit>0.9987</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0169</p_value>
            <p_value_desc>This test is considered nominally significant because a hierarchical procedure was used and was broken prior to this test.</p_value_desc>
            <method>Negative Binomial Regression</method>
            <param_type>Event Rate Ratio</param_type>
            <param_value>0.6643</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4749</ci_lower_limit>
            <ci_upper_limit>0.9291</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Weight at Week 24</title>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Weight at Week 24</title>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>kilograms (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="178"/>
                <count group_id="O3" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.93" spread="0.202"/>
                    <measurement group_id="O2" value="1.34" spread="0.205"/>
                    <measurement group_id="O3" value="1.23" spread="0.205"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline weight.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1565</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2992</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in BMI-for-age Z-score at Week 24</title>
        <description>Z-Score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from –infinity to + infinity; 0: same mean, &gt;0: a greater mean, and &lt;0: a lesser mean than the standard. BMI-for-age z-score was calculated by using Centers for Disease Control and Prevention (CDC) growth charts for the pediatric population.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure. Only participants who were &lt;20 years of age were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in BMI-for-age Z-score at Week 24</title>
          <description>Z-Score is a statistical measure to evaluate how a single data point compares to a standard. It describes whether a mean was above or below the standard and how unusual the measurement is with range from –infinity to + infinity; 0: same mean, &gt;0: a greater mean, and &lt;0: a lesser mean than the standard. BMI-for-age z-score was calculated by using Centers for Disease Control and Prevention (CDC) growth charts for the pediatric population.</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure. Only participants who were &lt;20 years of age were analyzed.</population>
          <units>z-score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="58"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0153" spread="0.04886"/>
                    <measurement group_id="O2" value="0.1132" spread="0.05081"/>
                    <measurement group_id="O3" value="0.0933" spread="0.05431"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline BMI z-score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1539</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0980</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0370</ci_lower_limit>
            <ci_upper_limit>0.2330</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2713</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0781</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0615</ci_lower_limit>
            <ci_upper_limit>0.2176</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time-to-First Pulmonary Exacerbation</title>
        <description>Time to first pulmonary exacerbation was assessed using Cox Regression. For participants who completed 24 weeks of treatment, participants without a pulmonary exacerbation before treatment completion were considered censored at the time of treatment completion or at the Week 24 Visit (whichever occurred last). For participants who prematurely discontinued study treatment, participants without a pulmonary exacerbation through the Week 24 Visit were considered censored at the time of the Week 24 Visit.</description>
        <time_frame>through Week 24</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-to-First Pulmonary Exacerbation</title>
          <description>Time to first pulmonary exacerbation was assessed using Cox Regression. For participants who completed 24 weeks of treatment, participants without a pulmonary exacerbation before treatment completion were considered censored at the time of treatment completion or at the Week 24 Visit (whichever occurred last). For participants who prematurely discontinued study treatment, participants without a pulmonary exacerbation through the Week 24 Visit were considered censored at the time of the Week 24 Visit.</description>
          <population>FAS.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Median time was not reached as less than 50% of participants had the event of interest.</measurement>
                    <measurement group_id="O2" value="NA">Median time was not reached as less than 50% of participants had the event of interest.</measurement>
                    <measurement group_id="O3" value="NA">Median time was not reached as less than 50% of participants had the event of interest.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using Cox proportional hazard regression, time is the time-to-first event or censoring, with adjustment for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0396</p_value>
            <method>Cox Proportional Hazard Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.692</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0385</p_value>
            <method>Cox Proportional Hazard Regression</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.691</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least 1 Pulmonary Exacerbation Event</title>
        <time_frame>through Week 24</time_frame>
        <population>FAS.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least 1 Pulmonary Exacerbation Event</title>
          <population>FAS.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="30.1"/>
                    <measurement group_id="O3" value="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>OR and 95% confidence intervals (CIs) are Mantel-Haenszel estimates. P values are from a Cochran-Mantel-Haenszel test stratified by sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), and percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0552</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.6565</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4266</ci_lower_limit>
            <ci_upper_limit>1.0103</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0512</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.6438</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4142</ci_lower_limit>
            <ci_upper_limit>1.0005</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24</title>
        <description>EQ-5D-3L: participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The 5 dimensional 3-level systems are converted into a single index utility score. Values for theoretically possible health states are calculated using a regression model and weighted according to the social preferences of the Unites States (US) general population. For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Euro Quality of Life Scale (EuroQol) 5-Dimension-3 Level (EQ-5D-3L) Index Score at Week 24</title>
          <description>EQ-5D-3L: participant rated questionnaire to assess health-related quality of life. It consists of EQ-5D descriptive system and EQ-5D Visual Analog Scale (VAS). EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems (1), some problems (2), and extreme problems (3). The 5 dimensional 3-level systems are converted into a single index utility score. Values for theoretically possible health states are calculated using a regression model and weighted according to the social preferences of the Unites States (US) general population. For this population, the possible EQ-5D-3L index scores ranges from -0.11 (that is, 3 for all 5 dimensions) to 1.0 (that is, 1 for all 5 dimensions), where higher scores indicate a better health state.</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="175"/>
                <count group_id="O3" value="170"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0006" spread="0.00739"/>
                    <measurement group_id="O2" value="0.0066" spread="0.00746"/>
                    <measurement group_id="O3" value="0.0100" spread="0.00757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline EQ-5D-3L index score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5604</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0142</ci_lower_limit>
            <ci_upper_limit>0.0262</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3613</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.0095</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.0109</ci_lower_limit>
            <ci_upper_limit>0.0298</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 24</title>
        <description>The EQ-5D-3L VAS records the participant’s self-rated health on a vertical, visual analogue scale where the best state a participant can imagine is marked 100 and the worst state a participant can imagine is marked 0, higher scores indicates a better health state.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in EQ-5D-3L VAS Score at Week 24</title>
          <description>The EQ-5D-3L VAS records the participant’s self-rated health on a vertical, visual analogue scale where the best state a participant can imagine is marked 100 and the worst state a participant can imagine is marked 0, higher scores indicates a better health state.</description>
          <population>FAS. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="173"/>
                <count group_id="O3" value="171"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.03"/>
                    <measurement group_id="O2" value="3.5" spread="1.04"/>
                    <measurement group_id="O3" value="2.8" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline EQ-5D-3L VAS score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1342</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>2.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.7</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3071</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.3</ci_lower_limit>
            <ci_upper_limit>4.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24</title>
        <description>The TSQM is a 14-item self-administered questionnaire which measures participants’ experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>FAS. Here, &quot;n&quot; signifies participants who were evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline in Treatment Satisfaction Questionnaire for Medication (TSQM) Domain Scores at Week 24</title>
          <description>The TSQM is a 14-item self-administered questionnaire which measures participants’ experiences with their medication on four dimensions: effectiveness, side effects, convenience and global satisfaction. For each dimension, responses are added and transformed to a scale from 0 to 100, where higher scores indicate greater satisfaction.</description>
          <population>FAS. Here, &quot;n&quot; signifies participants who were evaluable for specified category for each arm, respectively.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Effectiveness (n = 163, 156, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.30" spread="1.643"/>
                    <measurement group_id="O2" value="0.19" spread="1.666"/>
                    <measurement group_id="O3" value="0.50" spread="1.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Side Effects (n = 162, 154, 143)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.23" spread="1.119"/>
                    <measurement group_id="O2" value="-1.94" spread="1.141"/>
                    <measurement group_id="O3" value="-2.51" spread="1.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convenience (n = 163, 154, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.37" spread="1.504"/>
                    <measurement group_id="O2" value="4.98" spread="1.540"/>
                    <measurement group_id="O3" value="7.45" spread="1.579"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Global Satisfaction (n= 163, 154, 144)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.49" spread="1.863"/>
                    <measurement group_id="O2" value="-5.00" spread="1.906"/>
                    <measurement group_id="O3" value="-3.77" spread="1.956"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Effectiveness: analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline TSQM effectiveness score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0160</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.03</ci_lower_limit>
            <ci_upper_limit>9.96</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Effectiveness: analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0126</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.80</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>10.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Side Effects: analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline TSQM side effects score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0074</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.23</ci_lower_limit>
            <ci_upper_limit>-1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Side Effects: analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0029</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>-4.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.85</ci_lower_limit>
            <ci_upper_limit>-1.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Convenience: analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline TSQM convenience score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7721</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>0.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.50</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Convenience: analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1472</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.09</ci_lower_limit>
            <ci_upper_limit>7.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Global Satisfaction: analysis was performed using MMRM model including treatment, visit, and treatment-by-visit interaction as fixed effects with adjustments for sex (male versus female), age group at baseline (&lt;18 versus &gt;=18 years old), percent predicted FEV1 severity at Screening (&lt;70 versus &gt;=70), and baseline TSQM global satisfaction score.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0345</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>5.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>10.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Global Satisfaction: analysis was performed as described in Statistical Analysis 1.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0109</p_value>
            <method>MMRM</method>
            <param_type>LS Mean Difference</param_type>
            <param_value>6.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.55</ci_lower_limit>
            <ci_upper_limit>11.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)</title>
        <description>AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Nonserious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or that was newly developed at or after the initial dosing of study drug to 28 days after the last dose of study drug is considered treatment-emergent.</description>
        <time_frame>up to Week 28</time_frame>
        <population>Safety Set (SS) included all randomized participants who received any amount of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O3">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Treatment-Emergent Adverse Events (SAEs)</title>
          <description>AE: any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Nonserious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, in-patient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. Any AE that increased in severity or that was newly developed at or after the initial dosing of study drug to 28 days after the last dose of study drug is considered treatment-emergent.</description>
          <population>Safety Set (SS) included all randomized participants who received any amount of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="183"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants With Treatment-Emergent AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants With Treatment-Emergent SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)</title>
        <description>Ctrough, Ctrough, avg, C3-6h, and C3-6h, avg for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 15, and Weeks 4 and 8 and Ctrough, ave is average of individual pre-dose observed concentrations across Weeks 4, 8, and 16. This outcome was not planned to be assessed in Placebo arm.</description>
        <time_frame>For C3-6h: 3 to 6 hours after morning dose on Day 1 and 15, Week 4 and 8; For C3-6h,avg 3 to 6 hours after morning dose on Day 15, Week 4 and 8; For Ctrough and Ctrough,avg: before morning dose on Week 4, 8, and 16</time_frame>
        <population>Pharmacokinetic (PK) population included all randomized participants who received at least one dose of study drug and had a PK assessment. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure and “n” signifies participants evaluable for specified category for each arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>LUM 600 mg qd/IVA 250 mg q12h</title>
            <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
          </group>
          <group group_id="O2">
            <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
            <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose Concentration (Ctrough), Average Pre-dose Concentration (Ctrough,Avg), 3 to 6 Hours Post-dose Concentration (C3-6h), and Average 3 to 6 Hours Post-dose Concentration (C3-6h,Avg)</title>
          <description>Ctrough, Ctrough, avg, C3-6h, and C3-6h, avg for lumacaftor, M28 lumacaftor (lumacaftor metabolite), ivacaftor, M1 ivacaftor (ivacaftor metabolite), and M6 ivacaftor (ivacaftor metabolite) were calculated. C3-6h,ave is average of individual 3 to 6 hours post-dose observed concentrations across Day 15, and Weeks 4 and 8 and Ctrough, ave is average of individual pre-dose observed concentrations across Weeks 4, 8, and 16. This outcome was not planned to be assessed in Placebo arm.</description>
          <population>Pharmacokinetic (PK) population included all randomized participants who received at least one dose of study drug and had a PK assessment. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure and “n” signifies participants evaluable for specified category for each arm, respectively.</population>
          <units>microgram per milliliter (mcg/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="180"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>LUM, Day 1: C3-6h (n = 180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="12.5"/>
                    <measurement group_id="O2" value="18.4" spread="8.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Day 15: Ctrough (n = 172, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.56" spread="5.33"/>
                    <measurement group_id="O2" value="14.1" spread="6.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Day 15: C3-6 (n = 167, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1" spread="11.5"/>
                    <measurement group_id="O2" value="23.6" spread="8.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Week 4: Ctrough (n = 172, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.75" spread="5.05"/>
                    <measurement group_id="O2" value="13.4" spread="6.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Week 4: C3-6 (n = 170, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="11.2"/>
                    <measurement group_id="O2" value="24.2" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Week 8: Ctrough (n = 173, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.43" spread="5.60"/>
                    <measurement group_id="O2" value="13.4" spread="6.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Week 8: C3-6 (n = 165, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.2" spread="11.2"/>
                    <measurement group_id="O2" value="24.4" spread="8.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM, Week 16: Ctrough (n = 165, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.95" spread="4.99"/>
                    <measurement group_id="O2" value="13.5" spread="7.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Day 1: C3-6h (n = 180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.220" spread="0.107"/>
                    <measurement group_id="O2" value="0.179" spread="0.0811"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Day 15: Ctrough (n = 172, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="0.614"/>
                    <measurement group_id="O2" value="1.48" spread="0.590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Day 15: C3-6 (n = 167, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.606"/>
                    <measurement group_id="O2" value="1.49" spread="0.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Week 4: Ctrough (n = 172, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.646"/>
                    <measurement group_id="O2" value="1.48" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Week 4: C3-6 (n = 170, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.635"/>
                    <measurement group_id="O2" value="1.49" spread="0.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Week 8: Ctrough (n = 173, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.684"/>
                    <measurement group_id="O2" value="1.53" spread="0.674"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Week 8: C3-6 (n = 165, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.658"/>
                    <measurement group_id="O2" value="1.56" spread="0.669"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM, Week 16: Ctrough (n = 165, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.769"/>
                    <measurement group_id="O2" value="1.57" spread="0.757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Day 1: C3-6h (n = 180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.624"/>
                    <measurement group_id="O2" value="1.24" spread="0.630"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Day 15: Ctrough (n = 172, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.123"/>
                    <measurement group_id="O2" value="0.115" spread="0.123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Day 15: C3-6 (n = 167, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.557" spread="0.311"/>
                    <measurement group_id="O2" value="0.413" spread="0.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Week 4: Ctrough (n = 172, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.142" spread="0.107"/>
                    <measurement group_id="O2" value="0.105" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Week 4: C3-6 (n = 170, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.638" spread="0.325"/>
                    <measurement group_id="O2" value="0.456" spread="0.235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Week 8: Ctrough (n = 173, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.130" spread="0.101"/>
                    <measurement group_id="O2" value="0.0894" spread="0.0726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Week 8: C3-6 (n = 165, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.648" spread="0.364"/>
                    <measurement group_id="O2" value="0.470" spread="0.295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA, Week 16: Ctrough (n = 165, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.133" spread="0.131"/>
                    <measurement group_id="O2" value="0.0834" spread="0.0622"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Day 1: C3-6h (n = 180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.46" spread="1.29"/>
                    <measurement group_id="O2" value="2.41" spread="1.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Day 15: Ctrough (n = 172, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.665" spread="0.578"/>
                    <measurement group_id="O2" value="0.511" spread="0.530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Day 15: C3-6 (n = 167, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="0.981"/>
                    <measurement group_id="O2" value="1.71" spread="0.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Week 4: Ctrough (n = 172, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.628" spread="0.492"/>
                    <measurement group_id="O2" value="0.450" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Week 4: C3-6 (n = 170, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.21" spread="1.01"/>
                    <measurement group_id="O2" value="1.76" spread="0.932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Week 8: Ctrough (n = 173, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.584" spread="0.451"/>
                    <measurement group_id="O2" value="0.404" spread="0.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Week 8: C3-6 (n = 165, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="1.06"/>
                    <measurement group_id="O2" value="1.78" spread="0.975"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-1 IVA, Week 16: Ctrough (n = 165, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.589" spread="0.519"/>
                    <measurement group_id="O2" value="0.396" spread="0.319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Day 1: C3-6h (n = 180, 175)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.976" spread="0.877"/>
                    <measurement group_id="O2" value="0.927" spread="0.875"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Day 15: Ctrough (n = 172, 176)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.68" spread="1.31"/>
                    <measurement group_id="O2" value="1.67" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Day 15: C3-6 (n = 167, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.03" spread="1.96"/>
                    <measurement group_id="O2" value="2.87" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Week 4: Ctrough (n = 172, 178)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.66" spread="1.36"/>
                    <measurement group_id="O2" value="1.46" spread="0.938"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Week 4: C3-6 (n = 170, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.07" spread="1.92"/>
                    <measurement group_id="O2" value="2.49" spread="1.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Week 8: Ctrough (n = 173, 174)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.52" spread="1.12"/>
                    <measurement group_id="O2" value="1.31" spread="0.946"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Week 8: C3-6 (n = 165, 171)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.96" spread="1.86"/>
                    <measurement group_id="O2" value="2.36" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-6 IVA, Week 16: Ctrough (n = 165, 164)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.40" spread="1.11"/>
                    <measurement group_id="O2" value="1.33" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM: Ctrough,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.49" spread="3.93"/>
                    <measurement group_id="O2" value="13.5" spread="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUM: C3-6h,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="8.63"/>
                    <measurement group_id="O2" value="24.0" spread="7.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM: Ctrough,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.31" spread="0.628"/>
                    <measurement group_id="O2" value="1.51" spread="0.614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M-28 LUM: C3-6h,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="0.596"/>
                    <measurement group_id="O2" value="1.51" spread="0.585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA: Ctrough,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.137" spread="0.0773"/>
                    <measurement group_id="O2" value="0.0989" spread="0.0644"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA: C3-6h,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.614" spread="0.271"/>
                    <measurement group_id="O2" value="0.445" spread="0.193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1-IVA: Ctrough,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.606" spread="0.350"/>
                    <measurement group_id="O2" value="0.441" spread="0.293"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M1-IVA: C3-6h,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.11" spread="0.817"/>
                    <measurement group_id="O2" value="1.74" spread="0.726"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6-IVA: Ctrough,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.57" spread="0.992"/>
                    <measurement group_id="O2" value="1.44" spread="0.861"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>M6-IVA: C3-6h,ave (n = 179, 181)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.04" spread="1.55"/>
                    <measurement group_id="O2" value="2.57" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Week 28</time_frame>
      <desc>Participants were analyzed as per actual treatment received. Other adverse events includes only non-serious AEs.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Placebo matched to LUM and IVA tablet q12h, up to Week 24.</description>
        </group>
        <group group_id="E2">
          <title>LUM 600 mg qd/IVA 250 mg q12h</title>
          <description>LUM 600 mg plus IVA 250 mg FDC tablet in the morning and IVA 250 mg film-coated tablet in the evening, up to Week 24.</description>
        </group>
        <group group_id="E3">
          <title>LUM 400 mg q12h/ IVA 250 mg q12h</title>
          <description>LUM 400 mg plus IVA 250 mg FDC tablet in the morning and in the evening, up to Week 24.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Implant site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Catheter site cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Seminoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 17.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="175" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="172" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Thrombocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Defect conduction intraventricular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis related diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cerumen impaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tympanic membrane hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ear canal erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Steatorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Faeces soft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastrointestinal motility disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Malabsorption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chapped lips</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Colonic haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Defaecation urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastrointestinal sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gingivitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rectal tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tongue coated</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Implant site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Medical device pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Milk allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="57" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>H1N1 influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sputum purulent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Mycobacterium abscessus infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Conjunctivitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Herpes dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oral fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oropharyngeal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pseudomonas bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Stoma site infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Viral rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Stoma site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Foreign body in eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory fume inhalation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Skeletal injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Stoma site erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vaccination complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vascular procedure complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Fungal test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood immunoglobulin E increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood phosphorus increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterium test positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood bicarbonate decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood phosphorus abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chest X-ray abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Glucose tolerance test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Haemoglobin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pseudomonas test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Red blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sputum abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urine calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitamin E decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Magnesium deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Vitamin K deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tendon pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tendon disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bradyphrenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Disturbance in social behaviour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urine odour abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nephropathy toxic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urine abnormality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Penile erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiration abnormal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhonchi</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Increased upper airway secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Increased viscosity of bronchial secretion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngeal erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Lung hyperinflation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Allergic cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchial obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Nasal turbinate hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pharyngeal exudate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Prolonged expiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pulmonary pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Respiratory tract irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rhinalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Throat tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pruritus allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Chloasma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Red man syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="182"/>
              </event>
              <event>
                <sub_title>Poor venous access</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="184"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="182"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-341-6777</phone>
      <email>medicalinfo@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

